Artiva Stock on Watch with EULAR Data and Jefferies in Play
Artiva Biotherapeutics shares closed at $6.97 Wednesday, up 1.5%, ahead of its Jefferies healthcare conference appearance and new data on its AlloNK cell therapy. EULAR will feature five AlloNK abstracts this week, including results from 31 rheumatology patients. The company’s market cap stands near $339 million. Artiva plans a Phase 3 trial in refractory rheumatoid arthritis after promising Phase 2a results.